Literature DB >> 15370595

Secondary intramedullary nailing after distraction osteogenesis: 30 patients followed for 2-12 years.

Elias Lambiris1, Andreas Papadopoulos, Aggeliki Karabasi, Athanasios Karageorgos.   

Abstract

BACKGROUND: There is no consensus about replacement of an external fixator by reamed intramedullary nailing in fracture cases. PATIENTS AND METHODS: We evaluated the outcome in 30 patients (33 segments) of secondary intramedullary nailing during the consolidation phase after callus distraction using an external device. The main reasons for nailing were docking site nonunion (17 patients), angular deformity or fracture of the lengthened area (8 patients) or intolerance of the external device (5 patients), in 11 patients combined with a delayed distracted callus maturation. The average follow-up time was 4 (2-12) years.
RESULTS: Intramedullary infection after nailing occurred in 1 case, and slight loss in callus length in 5 cases. Failure of union at the docking site with nail breakage occurred in 1 case. In the other patients, consolidation in the lengthened callus area and also union at the docking site were achieved on average 6 months after nailing.
INTERPRETATION: We believe that intramedullary nailing during the consolidation phase after bone lengthening or bone transport is a treatment option for delayed callus maturation or docking site nonunion, reducing prolonged use of the external fixator. Copyright 2004 Taylor & Francis

Entities:  

Mesh:

Year:  2004        PMID: 15370595     DOI: 10.1080/00016470410001286-1

Source DB:  PubMed          Journal:  Acta Orthop Scand        ISSN: 0001-6470


  1 in total

1.  Bone transport combined with bone graft and internal fixation versus simple bone transport in the treatment of large bone defects of lower limbs after trauma.

Authors:  Qiang Huang; Yi Bo Xu; Cheng Ren; Ming Li; Cheng Cheng Zhang; Lu Liu; Qian Wang; Yao Lu; Hua Lin; Zhong Li; Han Zhong Xue; Kun Zhang; Teng Ma
Journal:  BMC Musculoskelet Disord       Date:  2022-02-17       Impact factor: 2.362

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.